Higher tumor TIDE prediction scores were associated not only with poor immune checkpoint suppression therapy but also with poor patient survival under anti-PD1 and anti-CTLA4 therapy (Chen et al., 2021). The gene discussed is CTLA4; the disease is neoplasm.